A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma
A population pharmacokinetic/pharmacodynamic model of axi-cel in large B-cell lymphoma explains the observation that high tumor burden and low CAR T-cell expansion predict poor outcomes. This model suggests tumor debulking before CAR T infusion or deploying CAR T therapy in measurable residual disease-positive patients after first-line treatment could improve CAR T success rates. See related commentary by Altrock, p. 11.
Authors
- Ash A. Alizadeh (ORCID: https://orcid.org/0000-0002-5153-5625)
- Deborah Plana (ORCID: https://orcid.org/0000-0002-4218-1693)
- Amy E. Pomeroy (ORCID: https://orcid.org/0000-0001-9217-3539)
- Adam C. Palmer (ORCID: https://orcid.org/0000-0001-5028-7028)
- Yanguang Cao (ORCID: https://orcid.org/0000-0002-3974-9073)
- Brian J. Sworder (ORCID: https://orcid.org/0000-0002-5902-5507)
Institutions
- University of North Carolina at Chapel Hill (US)
- California Institute for Regenerative Medicine (US)
- Institute for Stem Cell Biology and Regenerative Medicine (IN)
- Massachusetts General Hospital (US)
- Center for Systems Biology (US)
- Stanford University (US)
Publication Details
- Journal
- Blood Cancer Discovery
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1158/2643-3230.bcd-25-0138
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00